SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Michelle Gilson was appointed to the Board of Directors effective August 1, 2026, and simultaneously appointed as chair of the Audit Committee. This is a clear executive appointment of a director and committee chair with relevant biotechnology and financial expertise. Board appointments and committee leadership changes are material governance events affecting the registrant's leadership structure.
View raw filing on EDGAR →John Pershing is appointed as Executive Vice President and Chief Human Resources Officer, effective October 2026, succeeding Matthew Pasch. Pershing brings extensive HR leadership experience from major retailers including Barnes & Noble, Canadian Tire, Ascena, and Best Buy.
View raw filing on EDGAR →David Barse was appointed as a Class II director of KinderCare's Board of Directors, effective August 3, 2026. The appointment includes an RSU award of $126,575 and reflects his extensive experience as a business leader, investor, and board member.
View raw filing on EDGAR →Thomas Surran was appointed as President and Chief Executive Officer and principal financial officer of Resideo Technologies effective August 3, 2026, following the completion of the ADI spin-off.
View raw filing on EDGAR →ADI appointed eight directors (including Christine Gorjanc, William Galvin, Cynthia Hostetler, Michael Kaufmann, Stephen O. LeClair, Nathan Sleeper, and Brian Walker) and six executive officers (Robert Aarnes as President and CEO, Michael Carlet as CFO, Jeannine Lane as General Counsel, Alicia Copeland as COO, Marco Cardazzi as Chief Merchandising Officer, and James Olender as CIO) effective upon consummation of the separation on August 3, 2026.
View raw filing on EDGAR →The exhibit announces the appointment of Dr. Zhifeng Li as Chief Technology Officer (CTO) of MAAS, effective August 4, 2026. The disclosure explicitly states this is "an important step in MAAS's strategic transformation into a full-stack AI industry platform" and describes his broad responsibilities for technology strategy, AI roadmap, platform architecture, and R&D management. This is a material executive appointment to a named officer role at a critical juncture in the company's AI transformation strategy.
View raw filing on EDGAR →The 6-K discloses the appointment of Howard Steinberg as Chief Legal Officer effective July 22, 2026, and Keren Maimon as Managing Director effective the same date. While the filing also mentions termination of an advisory services agreement with Pulsar Group, the principal disclosed actions are executive appointments. The CLO appointment is material given Steinberg's extensive background in legal, regulatory, and compliance roles at major financial institutions, which would be relevant to investor assessment of the company's governance and risk management.
View raw filing on EDGAR →Dr. Molly Carr was appointed as Chief Medical Officer of iBio effective July 31, 2026. The appointment includes compensatory arrangements (base salary of $470,000, 40% target bonus, and a 430,000-share inducement stock option award) and is material to the clinical-stage biotech company as it strengthens clinical leadership during a critical phase of pipeline advancement into the clinic.
View raw filing on EDGAR →Danka Radosavljevic was appointed Chief Operating Officer on July 31, 2026, a material executive position. While the disclosure also includes compensation details (base salary of $520,800 and 50% bonus target), the principal disclosed action is the appointment to the COO role. The appointment of a C-suite officer is material to investors assessing company leadership and governance.
View raw filing on EDGAR →Daniel C. Kleine was elected Chief Financial Officer effective July 30, 2026, a material appointment to a named executive officer role with associated compensation arrangements including a salary increase to $300,000 and a 20,000 RSU grant.
View raw filing on EDGAR →The filing discloses both the resignation of CEO Vincent J. Arnone (effective August 10, 2026) and the appointment of Ramesh Nuggihalli as the new Chief Executive Officer and President (effective August 10, 2026). While both events are disclosed, the principal action centers on the appointment of a new CEO following a months-long executive search process. The appointment is material to investors as it represents a significant leadership transition at the company. The compensatory arrangements disclosed in section (e) are ancillary to the appointment itself.
View raw filing on EDGAR →Charlie's Holdings appointed Henry Sicignano III as Chief Executive Officer, effective immediately on August 4, 2026. Sicignano, former CEO of 22nd Century Group, assumes leadership at a critical juncture for the company's regulatory and commercialization initiatives. Ryan Stump transitioned from COO to Board Member and strategic partnerships role.
View raw filing on EDGAR →The filing discloses the appointment of two new independent directors, Craig Hart and Nancy Novak, to MARA's board effective August 1, 2026, filling vacancies created by the resignations of Barbara Humpton and Georges Antoun. While both departures and appointments occur, the principal disclosed action centers on the appointment of the new directors with detailed biographical information and their specific roles (Hart on the Risk and Audit Committee). This is a material governance event affecting board composition at a public company.
View raw filing on EDGAR →The filing's principal disclosed action is the appointment of Darin Harper, the Company's Chief Financial Officer, as Chief Executive Officer effective August 3, 2026, following Tarun Lal's retirement. While the filing also discloses Lal's departure, Harper's appointment as CEO—a critical leadership role—is the dominant event. The filing extensively details Harper's background, compensation package ($650,000 base salary, 100% target bonus, 115% LTIP target, and a $6.5 million one-time equity grant), and employment agreement terms, reflecting the materiality of this executive succession to investors.
View raw filing on EDGAR →Daniel Lewis was appointed as Interim Chief Executive Officer effective immediately on August 3, 2026, following Founder Vishal Garg's mutual agreement to transition from the CEO role, representing a significant change in the company's leadership.
View raw filing on EDGAR →Michael E. Regan was elected as a Class of 2028 director on July 30, 2026, and appointed to the Audit Committee, Enterprise Risk Committee, and Finance Committee, bringing 35+ years of FDIC regulatory expertise. Diane Gigliotti was promoted to Senior Vice President and Chief Accounting Officer, assuming expanded responsibility for accounting strategy and financial reporting as a named executive officer.
View raw filing on EDGAR →VersaBank announced the appointment of Lawrence Chamberlain as Global Senior Vice President, Investor and Stakeholder Relations, effective immediately. This is a named executive appointment to a senior leadership role. The disclosure emphasizes his six-year consulting relationship with the Bank, his deep understanding of strategy, and his role at a critical inflection point for the company, making this a material executive appointment.
View raw filing on EDGAR →The filing discloses both a director departure (Ilene Eskenazi's resignation effective August 3, 2026) and a director appointment (Carrie Cassidy's appointment to the Board and Compensation Committee, also effective August 3, 2026). The principal disclosed action centers on the appointment of Cassidy, with detailed background on her qualifications, compensation terms ($50,000 annual retainer plus equity grant), and committee assignments. While a departure also occurred, the substantive focus and length of disclosure is on the new director appointment.
View raw filing on EDGAR →Kevin Kalicak was appointed as Chief Financial Officer and Treasurer of Portillo's, effective September 7, 2026, succeeding interim CFO Pamela Smith. The appointment includes a base salary of $500,000, a bonus target of 75%, a long-term incentive target of $750,000, and an inducement RSU grant of $825,000.
View raw filing on EDGAR →The filing discloses the appointment of Rhonda Davenport as Chief Human Resources Officer effective August 3, 2026. While the disclosure includes compensatory details (base salary of $375,000, sign-on bonus, STI and LTI targets, and severance plan eligibility), the principal action is the appointment of a named executive officer to a C-suite position. The compensation details are ancillary to the core event of her taking the CHRO role.
View raw filing on EDGAR →Cory S. Gunderson has been appointed President and Chief Executive Officer of Protiviti (Robert Half's subsidiary) effective January 1, 2027, and will become an executive officer of Robert Half. Joseph A. Tarantino is transitioning from CEO to Senior Managing Director as part of a long-term succession plan.
View raw filing on EDGAR →Anne Bramman has been appointed as Executive Vice President and Chief Financial Officer, effective August 19, 2026, with detailed compensation arrangements disclosed including base salary of $950,000, short-term incentive target of 150%, equity grants of $3,250,000, and sign-on awards totaling $1,750,000. This is a material C-suite appointment at a major retailer ($41.6B revenue) during an active CEO transition, making it highly material to investors.
View raw filing on EDGAR →Bernd Leukert was elected and appointed as a Class II director of Teradata's Board effective August 1, 2026, with a term expiring at the 2027 Annual Meeting. The filing explicitly states the Board approved his election and appointment to the Nominating and Governance Committee. This is a clear executive appointment event, material because board composition changes affect corporate governance and investor assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →Carl S. Carande was appointed to the Board of Directors of United Community Banks Inc effective August 1, 2026, increasing the Board from 12 to 13 directors. Carande was also appointed to the Risk Committee and the subsidiary bank's board, bringing 40 years of financial services and consulting experience including 25 years in senior leadership roles at KPMG.
View raw filing on EDGAR →The disclosure announces the Reserve Bank of India's approval of the re-appointment of Mr. Ajay Kumar Gupta as Executive Director for a further two-year term (November 27, 2026 to November 26, 2028), following earlier Board approval and pending shareholder approval at the August 21, 2026 Annual General Meeting. This is a material executive appointment requiring regulatory and shareholder approval.
View raw filing on EDGAR →Jim Rozakis was appointed President and COO effective August 1, 2026, representing a significant promotion from his prior role as Executive Vice President and COO. While the disclosure also includes compensatory arrangements (base salary of $900,000, target cash incentive of $1,125,000, target long-term incentive of $4,000,000, and one-time equity awards), the principal disclosed action is the appointment to the President role in connection with the separation of President and CEO titles. This is material as it reflects a material change in executive leadership structure.
View raw filing on EDGAR →OGE Energy's Board elected Richard E. Muncrief as a new director effective August 1, 2026. The disclosure centers on the appointment of a highly qualified executive (retired President and CEO of Devon Energy) to the Board, with assignment to the Nominating, Corporate Governance and Stewardship Committee and the Audit Committee. This is a material governance event affecting board composition and oversight.
View raw filing on EDGAR →Mettler-Toledo appointed Natalia Shuman as a director effective August 3, 2026, with the Board determining she qualifies as independent under NYSE listing standards. The Board also resolved to increase its size from nine to ten directors in connection with this appointment. Shuman brings extensive executive experience including CEO roles at MISTRAS Group and Bureau Veritas North America.
View raw filing on EDGAR →The exhibit announces the appointment of Michael Halstead as Chief Executive Officer of Helus Pharma (Cybin Inc.), effective immediately. Halstead is a highly experienced pharmaceutical executive with 25 years of industry experience, most recently President of Intra-Cellular Therapies, where he led the company through commercialization and its $14.6 billion sale to Johnson & Johnson. This is a material executive appointment at a critical juncture as the company prepares for Phase 3 topline data readout in Q4 2026.
View raw filing on EDGAR →The filing discloses the appointment of Indira Agarwal as Senior Vice President, Chief Financial Officer, effective August 1, 2026, succeeding Damon Audia who was promoted to President of PTx & Corporate Strategy. While the filing also documents Agarwal's compensatory arrangement (base salary of $600,000, incentive compensation, and severance terms), the principal disclosed action centers on her appointment to the CFO role and Audia's promotion to a new strategic position. The appointment of a new CFO is material to investors as it affects the company's financial leadership and governance structure.
View raw filing on EDGAR →Michael G. O'Rourke and Leonard S. Caronia were appointed to Esquire Financial Holdings' board of directors effective upon completion of the Signature merger on August 1, 2026. O'Rourke also assumed the role of President of the Signature division.
View raw filing on EDGAR →The section discloses the appointment of David Kutil as Chief Financial Officer on July 28, 2026, along with material terms of his employment agreement including base salary of $275,000 and bonus eligibility. While the section also mentions termination of Sefton Cohen as Chief Revenue Officer, the primary focus and detail is on Kutil's appointment to a named executive officer role, making exec_appointment the most salient event. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.
View raw filing on EDGAR →The press release announces the appointment of Cassie McLean as a member of the Management Board and Chief Executive Officer of the Care Delivery operating segment, effective August 1, 2026. This is a material executive appointment to a senior leadership role at a major global healthcare company. The disclosure also notes that Craig Cordola, the previous CEO of Care Delivery, has departed from that role, but the principal disclosed action is McLean's appointment to the Management Board.
View raw filing on EDGAR →Matthew Whitlock was appointed as Chief Investment Officer of Chiron Real Estate Inc. and Inter-American Management LLC effective August 3, 2026. The disclosure details his appointment, employment agreement with $400,000 base salary, equity inducement awards valued at $350,000, and severance provisions. While the section also describes Alfonzo Leon's transition from CIO to Strategic Advisor, the principal disclosed action centers on Whitlock's appointment to a senior executive role with substantial compensation and equity arrangements, making this an executive appointment event.
View raw filing on EDGAR →The press release announces the appointment of Michael J. Loparco as an independent non-executive director effective August 3, 2026. While the exhibit also discloses a proposed U.S. redomiciliation, the principal disclosed action is the director appointment. Loparco's extensive executive background (CEO of Symbotic and Jabil, current CEO of OrcaWorcs.ai, board member of Sanmina) and relevance to IperionX's manufacturing scale-up make this material to investors assessing board composition and governance capability.
View raw filing on EDGAR →John B. Eagan was appointed as General Counsel and Corporate Secretary effective August 1, 2026, succeeding Wm. Gordon Prescott who retired July 31, 2026. Eagan will oversee all legal affairs and serve on the Executive Management Committee.
View raw filing on EDGAR →The press release announces the appointment of two new directors to POET's Board of Directors effective August 1, 2026: Dr. Bardia Pezeshki and Jean F. Rankin. Both appointments are described with detailed biographical information highlighting their relevant expertise in technology, optical communications, governance, and corporate transactions. While the exhibit also discloses Jean-Louis Malinge's resignation, the principal disclosed action is the two director appointments, which would materially affect investor assessment of board composition and governance.
View raw filing on EDGAR →Jeffrey Naylor was appointed as an independent Class I director and Audit Committee Chair of Petco Health & Wellness Company, Inc., effective August 1, 2026, filling a vacancy created by Cameron Breitner's resignation. Naylor brings extensive retail and financial leadership experience, including prior service as CFO of TJX Companies and current board memberships at Synchrony Financial and Wayfair.
View raw filing on EDGAR →The section discloses both the appointment of Paul Sacks as Interim Chief Financial Officer (effective August 4, 2026) and the departure of Matthew Prusak from the same role. While both events are disclosed, the appointment of a CFO—a named executive officer—is the principal action requiring disclosure and is material to investors assessing the company's leadership continuity. The departure is secondary context explaining why the appointment was necessary.
View raw filing on EDGAR →The filing discloses the appointment of Nicole Rapport as Vice President and Chief Accounting Officer effective August 16, 2026, with detailed background, compensation terms ($285,000 base salary plus $125,000 minimum bonus), and eligibility for equity participation. While the filing also mentions Eugene Shnayderman's concurrent departure, the principal disclosed action centers on Rapport's appointment to a named executive officer role with specified compensation arrangements, making exec_appointment the most salient classification.
View raw filing on EDGAR →The disclosure centers on the appointment of Matthew Casaccia to the Board of Managers of Invesco Capital Management LLC (the Sponsor) effective August 3, 2026, with concurrent appointment to the Audit Committee. Although the filing also mentions the concurrent resignation of Jordan Krugman, the principal action disclosed is Casaccia's appointment to a governance role. The appointment of a board member and audit committee member at the sponsor of an ETF is material to investors in the fund.
View raw filing on EDGAR →The disclosure centers on the appointment of Matthew Casaccia to the Board of Managers of Invesco Capital Management LLC (the Sponsor) effective August 3, 2026, with concurrent appointment to the Audit Committee. Although the filing also mentions the concurrent resignation of Jordan Krugman, the principal action disclosed is Casaccia's appointment to a governance role. This is a material governance event affecting the fund's sponsor's board composition.
View raw filing on EDGAR →Julie Sawyer Montgomery was appointed as President and Chief Executive Officer of Danaher, effective October 1, 2026, and was also appointed to the Board and three Board committees, representing a major leadership succession at the company.
View raw filing on EDGAR →The filing discloses the appointment of James Ahlers as Chief Financial Officer effective July 30, 2026. While the disclosure includes compensatory details (base salary of $450,000, target bonus of 45%, and equity grants of 51,000 stock options and 25,500 RSUs), the principal action is the appointment of a named executive officer to a key financial leadership role. The appointment of a CFO is material to investors as it affects the company's financial reporting and governance structure.
View raw filing on EDGAR →The filing discloses the appointment of Myriam J. Curet, M.D. as a new Class II director to Mobia's Board, effective July 30, 2026, increasing the Board size from seven to eight members. Dr. Curet brings substantial medical and board experience from senior roles at Intuitive Surgical and current directorships at Inspire Medical Systems and Stereotaxis, Inc. This is a material governance event affecting board composition and leadership.
View raw filing on EDGAR →Matthew Bromberg was appointed to the Board of Directors effective July 29, 2026, following the IPO, with compensatory arrangements including a director retainer and RSU award.
View raw filing on EDGAR →The company appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, both reporting directly to the CEO. These material C-suite appointments strengthen the company's leadership structure for global expansion and commercialization of its drug pipeline as multiple Phase III registrational studies advance.
View raw filing on EDGAR →The 6-K discloses the appointment of Nancy Yang as an independent director, chairman of the compensation committee, and member of the audit and nominating committees effective August 1, 2026. While the filing also mentions the concurrent resignation of Heung Ping Wong, the primary substantive action disclosed is Ms. Yang's appointment to the Board with specific committee assignments and qualifications as an audit committee financial expert. This is material as it affects Board composition and governance structure.
View raw filing on EDGAR →The 6-K discloses the appointment of Ms. Qian Yi Amanda Chew as Chief Product Officer (CPO) by the Board of Directors, effective August 17, 2026. This is a named executive appointment to a C-suite officer position, representing a material change in leadership that would affect a reasonable investor's assessment of the company's management structure and strategic direction.
View raw filing on EDGAR →William Sherman was appointed to the Board of Directors effective July 31, 2026, and simultaneously appointed as interim chair of the Audit Committee and chair of the Compensation Committee.
View raw filing on EDGAR →